Optiver Holding’s Inovio Pharmaceuticals INO Stock Holding History

Optiver Holding’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24	Closed	-$56	–	2709
2025 Q3	$56	Buy	+24	New	+$46	﹤0.01%	2615

Other funds holding INO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Optiver Holding's INO Position: Q4 2025 in Review

Optiver Holding sold out of Inovio Pharmaceuticals (INO) in Q4 2025, closing a stake of 24 shares — an estimated $56 sold.

Optiver Holding first reported a position in INO in Q3 2025 and held it in 1 quarter. The position peaked at $56 in Q3 2025. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.

Optiver Holding reported no remaining Inovio Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 24 Inovio Pharmaceuticals shares in Q4 2025, an estimated $56.
Optiver Holding first reported a position in Inovio Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Optiver Holding's Inovio Pharmaceuticals position peaked at $56 in Q3 2025.
102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.